{"id":"W4379650819","doi":"10.1136/annrheumdis-2023-eular.1464","title":"AB1591 POLICY DRIVERS FOR MARKET PENETRATION OF ANTI-TNF BIOSIMILARS: MULTI-COUNTRY COMPARISONS","year":2023,"lang":"en","type":"article","venue":"","topic":"Biosimilars and Bioanalytical Methods","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University of Calgary; Centre for Advancing Health Outcomes; University of British Columbia","funders":"UCB Pharma; Jazz Pharmaceuticals; Nordic Pharma Group; Mylan; Biogen; Sanofi; Merck; Canadian Institutes of Health Research; Novartis; Pfizer; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Biosimilar; Procurement; Infliximab; Medicine; Penetration (warfare); Market penetration; Market share; Business; Marketing; Operations research; Tumor necrosis factor alpha; Internal medicine; Engineering","routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.009159322,0.000339444,0.0005979859,0.001699556,0.0002755501,0.002265159,0.0004958792,0.0009896745,0.008049916],"category_scores_gemma":[0.01817315,0.0002204611,0.00219115,0.002707761,0.00065842,0.001734099,0.001609552,0.0010615,0.0007373063],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008400137,"about_ca_system_score_gemma":0.0007597404,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007328788,"about_ca_topic_score_gemma":0.004193621,"domain_scores_codex":[0.993515,0.003849973,0.0003588911,0.0005917961,0.0006351839,0.001049193],"domain_scores_gemma":[0.9778174,0.01104743,0.008038589,0.0007673533,0.001441451,0.0008878889],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.006416188,0.0005357182,0.9374388,0.001031391,0.005939291,0.0004333591,0.0008631754,0.009978635,0.0008120445,0.005733903,0.004431724,0.02638561],"study_design_scores_gemma":[0.0002635847,0.001204627,0.9851677,0.0003026662,0.001321755,0.000201956,0.002619418,0.003164138,0.0004799954,0.001078718,0.004145159,0.00005017545],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9872801,0.001824221,0.0008390638,0.000667628,0.00003835816,0.0001035596,0.004162475,0.00001303758,0.005071599],"genre_scores_gemma":[0.9976965,0.0002119921,0.0002724541,0.0001144878,0.00001381393,0.00004171466,0.001372944,0.000007696857,0.0002685408],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.009159322,"threshold_uncertainty_score":0.04843974,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04815369307898426,"score_gpt":0.3436926202255529,"score_spread":0.2955389271465687,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}